Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus glucocorticoid for relapsed/refractory acquired hemophilia A
ChiCTR2000035067Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2020
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib in acquired haemophilia (AH), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall response rate at week 12 of treatment, Complete response (CR) rate at week 12 of treatment and 1 more. Started May 2020; status: recruiting.
02
Drugs
bortezomib
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on ChiCTR2000035067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035067.